The unapproved retatrutide market holds immense safety risks, and patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans.
The U.S. Court of Appeals for the Fourth Circuit upheld the preliminary injunction filed against alternative funding programs and related vendors, in a major win for Gilead Sciences’ civil case.
35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
Victory Medical Center Pharmacy issued a voluntary recall for three lots of its compounded glutathione vials due to elevated endotoxin levels.
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”
FDA’s Pharmaceutical Compounding Advisory Committee voted to add six of seven peptides to the 503A Bulk Drug Substance List, despite FDA scientists recommending against all of them because of limited evidence of their safety and effectiveness.
PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.
Read More about PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply